

**Seema Shah, M.D.**  
**7401 South Main St.**  
**Houston, Texas 77030**  
**Phone: (713) 799-2300**  
**Fax: (281)501-5966**

**Education:**

1976-79      Stanford University  
Palo Alto, California

1979-83      University of Puerto Rico  
Rio Piedras, Puerto Rico  
Degree: MD

**Postgraduate Training:**

1983-84      Straight Medicine Internship  
Baylor Affiliated Hospitals  
Houston, Texas

1884-86      Internal Medicine Residency  
Baylor College of Medicine  
Houston, Texas

1986-88      Clinical Fellow in Infectious Diseases  
Baylor College of Medicine  
Houston, Texas

**Appointments:**

Assistant Professor of Clinical Medicine  
Houston Methodist Institute for Academic Medicine  
July 1, 2014-present

Clinical Instructor, Department of Medicine  
(1995 to 2005)  
Baylor College of Medicine  
Houston, Texas

Department Chairman, Subspecialty, MacGregor  
Medical Association

**Medical Staff**

**Appointments:** Methodist Hospital  
Kindred Hospital  
Texas Orthopedic Hospital

**Professional Societies:** Alpha Omega Alpha Honor Medical Society  
Harris County Medical Society  
Texas Medical Association

**Clinical Research**

**Affiliation:** Active Member: Houston Methodist Research Institute  
(Houston, Texas)

**Present Committees:** Texas Medical Association  
Committee on Infectious Diseases  
2012-present

**Past Committees:** Clinical Medical Research - Chairman  
MacGregor Medical Association  
Houston, Texas

Service Improvement Committee – Chairman  
MacGregor Medical Association  
Houston, Texas

Physician Focus Group  
Health Service Committee  
Ryan White Planning Council

Infection Control Committee  
The Methodist Hospital  
Houston, Texas

Medical Performance Improvement Committee  
The Methodist Hospital  
Houston, Texas

**Certification:** National Board of Medical Examiners  
Texas State Board of Medical Examiners  
American Board of Internal Medicine  
Subspecialty Board of Infectious Diseases

- Practice:** 1988-5/2002 MacGregor Medical Association  
Houston, Texas
- 11/2009-7/2010 Cetero Research  
San Antonio, Texas
- 06/2002-12/16 Private Practice, Seema Shah, M.D.  
Houston Methodist Hospital, Houston Texas
- 01/16-present Fondren Orthopedic Group, Houston, Texas
- Lectures:** 06-29-1994 “Role of Primary Care Physicians  
in HIV Infection “ Accredited for 1 hour CME
- 11-19-1994 “Medical and Psychosocial Issues of HIV Infections”  
Accredited For 1 hour CME by the Houston Bar  
Association
- 06/1999 “Role of Oral Antibiotics in an Outpatient Setting”  
sponsored By Ortho-McNeil
- 05/2001 Update on Infectious Diseases
- 01/2008 Clostridia difficile colitis

**Licensure:** 1986-Present State of Texas

**Publications:** “Comparison of Antimicrobial Impregnation with tunneling of  
Long Term Intravenous Catheters: A Randomized Control  
Trial” Annals of Surgery, Aug 1 2005.

“Prominent Small Bowel Ga-67 Uptake Associated with  
Yersinial and Tuberculosis Enterocolitis. Brophy M. Lamki  
L, Barron B and Shah S. Clinical Nuclear Medicine,  
February 13 1995.

**Current Studies:** Multi-National, Multi-Center, Double Blind, Randomized Trial  
to Compare Safety and Efficacy of PAR-101 with oral  
Vancomycin for a C. difficile diarrhea.

Randomized Control Trial to compare antimicrobial  
impregnated central venous catheters with Tunneled  
catheters.

**Past Studies:**

Genotype Assisted Initial Nefinavir Study (GAIN)  
subinvestigator

“An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV infected subjects. APV 30005

“Performance of Lopinavir/Ritonavir as an Alternative Treatment Option (PLATO): A Randomized, Phase IV Study to Evaluate the Quality of Life of Subjects infected With HIV-1 and who are intolerant to Their Current Antiretroviral Therapy and Alter Therapy to Kaletra”

“A Phase III, randomized, multicenter, parallel, open-label study to compare the Efficacy, safety, and tolerability of GW433908, and Nelfinavir over 48 weeks in Antiretroviral therapy naïve HIV-1 infected Adults”

“Surveillance for Variant and Drug Resistant Strains of HIV in the United States” (in conjunction with Center for Disease Control)”

“#166-06-99 Norvir/Indinavir Combination Evaluation Study: A randomized, Controlled, open label comparison of continuing Indinavir Q8H vs. switching to Norvir/Indinavir 400 mg. BID” Protocol # M99-047

“A Randomized, Open-Label, Expanded Access Program to Evaluate the Safety Of Preveon (adefovir dipivoxil) at Two Dose Levels when Used in Combination with Other Antiretroviral Agents for the Treatment of Patients with HIV Infection Who Have Limited Treatment Options”

Ziagen Optimal Regimen and Resistance Observational Study (Zorro)

Hepatitis C Response Program

ABT-378/ritonavir, Early Access Program Protocol M99-046

Multi-Center, International, Double Blind Study comparing 256487 and Acyclovir For the suppression of ano-genital Herpes Infections in HIV-infected individuals.

Double-Blind, Multicenter Study Comparing Valacyclovir HCL with Famciclovir For the Treatment of Uncomplicated Herpes Zoster in Immunocompetent Patients 50 years of Age and Older.

An Open-Label Study of the Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected with HIV.

An Open-Label Safety Study of Oral Lamivudine in HIV positive patients unable to Tolerate other drugs.

Double-Blind, Multi-Center Study comparing Oral 882C87 with Oral Acyclovir for Treatment of localized Herpes Zoster in Immunocompromised Patients.

Randomized trial of Aztreonam and Clindamycin versus Imipenem/Cilastatin for the Treatment of Complicated Intra-abdominal Infections.